Open AccessImmunogenicity and Safety of AS03-adjuvanted H5N1 Influenza Vaccine in Children 6–35 Months of Age
Author(s) -
Joon Hyung Kim,
Mamadou Dramé,
Thanyawee Puthanakit,
Nan-Chang Chiu,
Khuanchai Supparatpinyo,
LiMin Huang,
Cheng-Hsun Chiu,
PoYen Chen,
Kao-Pin Hwang,
Jasur Danier,
Damien Friel,
Bruno Salaun,
Wayne Woo,
David W. Vaughn,
Bruce L. Innis,
Anne Schuind
Publication year - 2021
Publication title -
the pediatric infectious disease journal/the pediatric infectious disease journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.028
H-Index - 140
eISSN - 1532-0987
pISSN - 0891-3668
DOI - 10.1097/inf.0000000000003247
Subject(s) - immunogenicity , influenza a virus subtype h5n1 , medicine , safety profile , influenza vaccine , virology , reactogenicity , immunology , vaccination , immune system , adverse effect , virus
This phase 2 observer-blind, randomized, multicenter, dose-ranging study evaluated immunogenicity and safety of different formulations of an AS03-adjuvanted H5N1 influenza vaccine in children 6-35 months of age.